{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:02:25Z","timestamp":1784073745804,"version":"3.55.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>High doses of ampicillin are often used to achieve therapeutic drug concentrations in infants. A paradoxical antibiotic effect, often called the Eagle effect, occurs when increasing concentrations of antibiotic above a threshold results in decreased efficacy. It is unknown if infants treated with ampicillin are at risk for this paradoxical effect.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We identified infants &lt;28 days of age with <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>, <jats:italic toggle=\"yes\">Enterococcus<\/jats:italic> or <jats:italic toggle=\"yes\">Streptococcus agalactiae<\/jats:italic> (group B streptococcus) bloodstream infections from 1997 to 2012 and previously included in an ampicillin pharmacokinetic (PK) modeling study. We compared the odds of death for ampicillin dose, estimated time above the minimum inhibitory concentration (<jats:italic toggle=\"yes\">T<\/jats:italic> &gt; MIC) and PK parameters using separate logistic regression models. Adjusted logistic regression and Poisson models were used to calculate the odds of prolonged bacteremia \u22653 days and the duration of bacteremia, respectively, for dose, <jats:italic toggle=\"yes\">T<\/jats:italic> &gt; MIC and multiple PK parameters.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among 1272 infants meeting inclusion criteria, odds of death 7 or 30 days after the positive blood culture were not consistent with a paradoxical effect across any of the dosing regimens or PK parameters evaluated. The odds of prolonged bacteremia was lowest at the lowest dose category and the lowest daily dose category but not associated with the area-under-the-concentration time curve from 0 to 24 hours, or the maximum or minimum concentrations at steady state. <jats:italic toggle=\"yes\">T<\/jats:italic> &gt; MIC of \u226550% of the dosing interval was associated with decreased duration of bacteremia and odds of prolonged bacteremia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>It is unlikely that a paradoxical antibiotic effect will have a clinical correlate when ampicillin is used for neonatal bacteremia. A <jats:italic toggle=\"yes\">T<\/jats:italic> &gt; MIC \u226550% decreased both duration of bacteremia and odds of prolonged bacteremia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002663","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T17:26:23Z","timestamp":1585761983000},"page":"725-729","source":"Crossref","is-referenced-by-count":10,"title":["Paradoxical Antibiotic Effect of Ampicillin"],"prefix":"10.1097","volume":"39","author":[{"given":"Jessica E.","family":"Ericson","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph P.","family":"Hornik","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel G.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reese H.","family":"Clark","sequence":"additional","affiliation":[{"name":"Pediatrix-Obstetrix Center for Research and Education, Sunrise, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana H.","family":"Tremoulet","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Brian","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Best Pharmaceuticals for Children Act \u2013 Pediatric Trials Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0033-1361933","article-title":"Medication use in the neonatal intensive care unit.","volume":"31","author":"Hsieh","year":"2014","journal-title":"Am J Perinatol"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1542\/peds.2005-1707","article-title":"Reported medication use in the neonatal intensive care unit: data from a large national data set.","volume":"117","author":"Clark","year":"2006","journal-title":"Pediatrics"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.88.1.99","article-title":"The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms.","volume":"88","author":"Eagle","year":"1948","journal-title":"J Exp Med"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.107.2767.44","article-title":"A paradoxical zone phenomenon in the bactericidal action of penicillin in vitro.","volume":"107","author":"Eagle","year":"1948","journal-title":"Science"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/158.1.23","article-title":"The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis.","volume":"158","author":"Stevens","year":"1988","journal-title":"J Infect Dis"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/jac\/5.5.613","article-title":"Paradoxical effect of aminoglycoside antibiotics on the growth of Gram-negative bacilli.","volume":"5","author":"Lorian","year":"1979","journal-title":"J Antimicrob Chemother"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1128\/AAC.34.12.2331","article-title":"Correlation of quinolone MIC and inhibition of DNA, RNA, and protein synthesis and induction of the SOS response in Escherichia coli.","volume":"34","author":"Piddock","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000238518","article-title":"Effect of antibiotic protein binding on the killing rate of Staphylococcus aureus and on the paradoxical phenomenon.","volume":"33","author":"Odenholt","year":"1987","journal-title":"Chemotherapy"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1128\/AAC.31.7.1014","article-title":"Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies.","volume":"31","author":"Stratton","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000237998","article-title":"High concentration of ampicillin and the Eagle effect among gram-negative rods.","volume":"27","author":"Goldstein","year":"1981","journal-title":"Chemotherapy"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jac\/15.4.507","article-title":"Paradoxical effect of penicillin in-vivo.","volume":"15","author":"Griffiths","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jpeds.2016.07.011","article-title":"Electronic health records and pharmacokinetic modeling to assess the relationship between ampicillin exposure and seizure risk in neonates.","volume":"178","author":"Hornik","year":"2016","journal-title":"J Pediatr"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12098-014-1585-2","article-title":"The Pediatrix BabySteps\u00ae Data Warehouse\u2013a unique national resource for improving outcomes for neonates.","volume":"82","author":"Spitzer","year":"2015","journal-title":"Indian J Pediatr"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1542\/peds.2009-0913","article-title":"New intrauterine growth curves based on United States data.","volume":"125","author":"Olsen","year":"2010","journal-title":"Pediatrics"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1128\/AAC.02374-13","article-title":"Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design.","volume":"58","author":"Tremoulet","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20230912","article-title":"Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories.","volume":"57:e00203\u2013e00219","author":"Humphries","year":"2019","journal-title":"J Clin Microbiol"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jpeds.2018.12.002","article-title":"Risk factors for complications in children with Staphylococcus aureus bacteremia.","volume":"208","author":"Hamdy","year":"2019","journal-title":"J Pediatr"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams.","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.clinthera.2005.11.007","article-title":"Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.","volume":"27","author":"Ellis","year":"2005","journal-title":"Clin Ther"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1086\/430350","article-title":"Eagle effect in Corynebacterium diphtheriae.","volume":"191","author":"Grandi\u00e8re-P\u00e9rez","year":"2005","journal-title":"J Infect Dis"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jac\/33.3.585","article-title":"Paradoxical dose effect of continuously administered cloxacillin in treatment of tolerant Staphylococcus aureus endocarditis in rats.","volume":"33","author":"Voorn","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jac\/17.5.684","article-title":"Paradoxical effect of penicillin in vivo.","volume":"17","author":"George","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0002-9343(50)90425-6","article-title":"Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels.","volume":"9","author":"Eagle","year":"1950","journal-title":"Am J Med"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM195303192481201","article-title":"\u201cContinuous\u201d vs. \u201cdiscontinuous\u201d therapy with penicillin; the effect of the interval between injections on therapeutic efficacy.","volume":"248","author":"Eagle","year":"1953","journal-title":"N Engl J Med"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/AAC.36.3.540","article-title":"Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis.","volume":"36","author":"Snydman","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/00006454-199312000-00001","article-title":"Microbiologic efficacy of antibacterial drugs for acute otitis media.","volume":"12","author":"Klein","year":"1993","journal-title":"Pediatr Infect Dis J"},{"key":"R31-20230912","first-page":"S209","article-title":"Eradication of bacterial pathogens from middle ear infections.","volume":"14","author":"Howie","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"12 suppl 3","key":"R32-20230912","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1097\/00006454-199312003-00005","article-title":"Clarithromycin vs. amoxicillin suspensions in the treatment of pediatric patients with acute otitis media.","volume":"12","author":"Pukander","year":"1993","journal-title":"Pediatr Infect Dis J"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00006454-199603000-00015","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.","volume":"15","author":"Craig","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.diagmicrobio.2018.01.020","article-title":"Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations.","volume":"91","author":"Kuti","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"e1242","DOI":"10.1542\/peds.2010-3487","article-title":"Extrapolation of adult data and other data in pediatric drug-development programs.","volume":"128","author":"Dunne","year":"2011","journal-title":"Pediatrics"},{"key":"R36-20230912","first-page":"190","article-title":"Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.","volume":"16","author":"Langan","year":"2014","journal-title":"Crit Care Resusc"},{"key":"R37-20230912","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/pbc.25287","article-title":"Population pharmacokinetics of the piperacillin component of piperacillin\/tazobactam in pediatric oncology patients with fever and neutropenia.","volume":"62","author":"Cies","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0732-8893(96)00162-9","article-title":"Antimicrobial resistance issues of the future.","volume":"25","author":"Craig","year":"1996","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R39-20230912","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1128\/AAC.01586-06","article-title":"Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.","volume":"51","author":"Mouton","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R40-20230912","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0022-3476(74)80684-0","article-title":"Pharmacologic studies in neonates given large dosages of ampicillin.","volume":"84","author":"Kaplan","year":"1974","journal-title":"J Pediatr"},{"issue":"suppl 5","key":"R41-20230912","doi-asserted-by":"crossref","first-page":"S518","DOI":"10.1093\/clinids\/8.Supplement_5.S518","article-title":"Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn.","volume":"8","author":"Sutton","year":"1986","journal-title":"Rev Infect Dis"},{"key":"R42-20230912","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1542\/peds.64.5.627","article-title":"Comparative pharmacokinetics of amoxicillin and ampicillin in infants and children.","volume":"64","author":"Ginsburg","year":"1979","journal-title":"Pediatrics"},{"key":"R43-20230912","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/infdis\/129.4.461","article-title":"Pharmacokinetics of ampicillin in the newborn infant.","volume":"129","author":"Yoshioka","year":"1974","journal-title":"J Infect Dis"},{"key":"R44-20230912","doi-asserted-by":"crossref","first-page":"e02307","DOI":"10.1128\/AAC.02307-18","article-title":"Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans.","volume":"63","author":"Bulitta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R45-20230912","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/jp.2010.154","article-title":"Effect of ampicillin on bleeding time in very low birth-weight neonates during the first week after birth.","volume":"31","author":"Sheffield","year":"2011","journal-title":"J Perinatol"},{"key":"R46-20230912","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1345\/aph.17228","article-title":"Ampicillin-induced neurotoxicity in very-low-birth-weight neonates.","volume":"32","author":"Shaffer","year":"1998","journal-title":"Ann Pharmacother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T23:10:54Z","timestamp":1694560254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002663"}},"subtitle":["Use of a Population Pharmacokinetic Model to Evaluate a Clinical Correlate of the Eagle Effect in Infants With Bacteremia"],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002663","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,8]]}}}